- Home
- GDTC vs KALA Comparison
GDTC vs KALA Comparison
Compare GDTC & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- KALA
- Stock Information
- Founded
- GDTC 2018
- KALA 2009
- Country
- GDTC Singapore
- KALA United States
- Employees
- GDTC N/A
- KALA N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- KALA Health Care
- Exchange
- GDTC Nasdaq
- KALA Nasdaq
- Market Cap
- GDTC 21.5M
- KALA 26.2M
- IPO Year
- GDTC 2023
- KALA 2017
- Fundamental
- Price
- GDTC $1.89
- KALA $7.14
- Analyst Decision
- GDTC Buy
- KALA Strong Buy
- Analyst Count
- GDTC 1
- KALA 3
- Target Price
- GDTC $5.00
- KALA $14.00
- AVG Volume (30 Days)
- GDTC 18.1K
- KALA 198.2K
- Earning Date
- GDTC 01-01-0001
- KALA 08-05-2025
- Dividend Yield
- GDTC N/A
- KALA N/A
- EPS Growth
- GDTC N/A
- KALA N/A
- EPS
- GDTC N/A
- KALA N/A
- Revenue
- GDTC $368,838.00
- KALA N/A
- Revenue This Year
- GDTC $5.37
- KALA N/A
- Revenue Next Year
- GDTC N/A
- KALA N/A
- P/E Ratio
- GDTC N/A
- KALA N/A
- Revenue Growth
- GDTC N/A
- KALA N/A
- 52 Week Low
- GDTC $1.20
- KALA $2.92
- 52 Week High
- GDTC $4.05
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- GDTC 37.08
- KALA 59.52
- Support Level
- GDTC $1.85
- KALA $5.35
- Resistance Level
- GDTC $1.95
- KALA $8.49
- Average True Range (ATR)
- GDTC 0.10
- KALA 0.81
- MACD
- GDTC -0.02
- KALA 0.17
- Stochastic Oscillator
- GDTC 28.00
- KALA 57.01
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.